Science Explorer Back to mapMap

Most cited papers from Klinikum Mutterhaus der Borromäerinnen

What are the most cited papers from Klinikum Mutterhaus der Borromäerinnen?

The most cited paper from Klinikum Mutterhaus der Borromäerinnen is "Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial" (Salah‐Eddin Al‐Batran et al., 2019), with 2,700 citations. Next come "Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)" (1,139) and "Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial" (751).

Showing 50 of 60 papers. Every paper with more than 50 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Salah‐Eddin Al‐Batran et al. · The Lancet 11 Apr 2019 2,700
2 Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Michael G. Pfreundschuh et al. · The Lancet Oncology 17 Jan 2008 1,139
3 Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial Salah‐Eddin Al‐Batran et al. · The Lancet Oncology 22 Oct 2016 751
4 Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials Allan Lipton, Karim S. Fizazi, Alison Stopeck et al. · European Journal of Cancer 10 Sep 2012 592
5 A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy M. D. Green, Heinz Koelbl, José Baselga et al. · Annals of Oncology Open access 17 Dec 2002 588
6 Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial Michael Untch et al. · The Lancet Oncology 8 Feb 2016 422
7 Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Jean‐Jacques Body, Ingo Diel, Michail R Lichinitser et al. · Annals of Oncology Open access Sep 2003 416
8 Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein Matthias Baumann et al. · Journal of Neurology Neurosurgery & Psychiatry 13 Aug 2014 314
9 Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Salah Eddin Al-Batran, Joerg Thomas Hartmann, Ralf‐Dieter Hofheinz et al. · Annals of Oncology Open access Aug 2008 281
10 Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial Viola Poeschel et al. · The Lancet Open access Dec 2019 257
11 Antimicrobial therapy of unexplained fever in neutropenic patients Hartmut Link, A. B�hme, Oliver A. Cornely et al. · Annals of Hematology Oct 2003 251
12 Blunted Cortisol Responses to Psychosocial Stress in Asthmatic Children: A General Feature of Atopic Disease? Angelika Buske-Kirschbaum, Kristin von Auer, Silke Krieger et al. · Psychosomatic Medicine Sep 2003 222
13 Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Barbara Waßmann, Heike Pfeifer, Michael Beda Stadler et al. · Blood Open access 7 Apr 2005 204
14 Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial Ulrike Anneliese Nitz et al. · Breast Cancer Research and Treatment Open access 29 Jun 2017 190
15 Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial Karolin Behringer et al. · The Lancet 21 Dec 2014 184
16 Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial Ursula Nestle et al. · The Lancet Oncology 12 Mar 2020 182
17 Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) Werner Heinz, Dieter Buchheidt, Maximilian Christopeit et al. · Annals of Hematology Open access 30 Aug 2017 177
18 Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study Thierry André, Jose M. Reyes-Vidal, Lætitia Fartoux et al. · British Journal of Cancer Open access 26 Aug 2008 176
19 High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas María A. Tichomirowa et al. · European Journal of Endocrinology Open access 14 Jul 2011 174
20 The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+) Salah‐Eddin Al‐Batran, Claudia Pauligk, Nils Homann et al. · European Journal of Cancer 11 Oct 2012 168
21 Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer Ingo Diel, Jean‐Jacques Body, Michail R Lichinitser et al. · European Journal of Cancer 30 May 2004 165
22 West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer Ulrike Anneliese Nitz et al. · Journal of Clinical Oncology 20 Feb 2019 148
23 Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results Oleg Gluz et al. · JNCI Journal of the National Cancer Institute 13 Nov 2017 135
24 Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study Eric Van Cutsem, Corrado Boni, Josep M. Tabernero et al. · Annals of Oncology Open access 22 Nov 2014 133
25 Vertebral body stenting: a new method for vertebral augmentation versus kyphoplasty Robert Rotter, Heiner Martin, Sebastian Fuerderer et al. · European Spine Journal Open access 28 Feb 2010 129
26 Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial Sibylle Loibl et al. · Annals of Oncology Open access 3 Nov 2016 120
27 EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 Stefan Hubert Boeck, Andreas Jung, Rüdiger Paul Laubender et al. · British Journal of Cancer Open access 20 Nov 2012 117
28 Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer Chris Manegold, Bengt Bergman, Assaad Chemaissani et al. · Annals of Oncology Open access Jun 1997 114
29 Wholesome Nutrition: an example for a sustainable diet Karl von Koerber, Nadine Bader, Claus Leitzmann · Proceedings of The Nutrition Society Open access 9 Aug 2016 113
30 Acute exposure to nocturnal train noise induces endothelial dysfunction and pro-thromboinflammatory changes of the plasma proteome in healthy subjects Johannes Herzog, Frank Patrick Schmidt, Omar Hahad et al. · Basic Research in Cardiology Open access 29 Oct 2019 107
31 FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group Ralf‐Dieter Hofheinz et al. · Journal of Clinical Oncology 16 Jun 2022 100
32 High-risk additional chromosomal abnormalities at low blast counts herald death by CML Rüdiger Hehlmann et al. · Leukemia Open access254 authors 7 May 2020 93
33 Hypothalamic-Pituitary-Adrenal Axis Function and the Cellular Immune Response in Former Preterm Children Angelika Buske-Kirschbaum, Silke Krieger, Chloe Wilkes et al. · The Journal of Clinical Endocrinology & Metabolism 14 Jun 2007 90
34 Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial C.-H. Köhne, Raphael Catane, B. Klein et al. · British Journal of Cancer Open access Sep 2003 89
35 Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV Manuel Barreto Miranda et al. · Leukemia Open access 9 Feb 2016 88
36 Clinical use and outcome of extracorporeal membrane oxygenation in patients with pulmonary embolism Lukas Hobohm, Ingo Sagoschen, Andreas Habertheuer et al. · Resuscitation Open access 13 Oct 2021 87
37 The hip fracture surgery in elderly patients (HIPELD) study to evaluate xenon anaesthesia for the prevention of postoperative delirium: a multicentre, randomized clinical trial Mark Coburn et al. · British Journal of Anaesthesia Open access 16 Dec 2017 80
38 Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer Michael Clemens, Oleg A. Gladkov, Elaina M. Gartner et al. · Breast Cancer Research and Treatment Open access 29 Dec 2014 80
39 Effect of dietary phytochemicals on cancer development (review) Ali Reza Waladkhani, Michael Clemens · International Journal of Molecular Medicine Apr 1998 80
40 Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer Stefan Hubert Boeck, Thomas Hoehler, Gernot Seipelt et al. · Annals of Oncology Open access 25 Oct 2007 78
41 Use of routine thoracic and abdominal computed tomography scans for assessing bone mineral density and detecting osteoporosis Milka Marinova, Bob Edon, Karsten Wolter et al. · Current Medical Research and Opinion 26 Aug 2015 78
42 Overweight and basal metabolic rate in boys with attention-deficit/hyperactivity disorder Ralph Hubel, Jana Jaß, Alexander M. Marcus et al. · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity Sep 2006 75
43 Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer Willem W ten Bokkel Huinink, Bengt Bergman, Assad Chemaissani et al. · Lung Cancer Nov 1999 73
44 A multicentre randomised controlled trial of the McGrath ™ Mac videolaryngoscope versus conventional laryngoscopy Marc Kriege, Ruediger R. Noppens, Timothy P. Turkstra et al. · Anaesthesia Open access 16 Mar 2023 72
45 Increased responsiveness of the hypothalamus–pituitary–adrenal (HPA) axis to stress in newborns with atopic disposition Angelika Buske-Kirschbaum, Sonja Fischbach, Wolfgang Rauh et al. · Psychoneuroendocrinology 25 Nov 2003 71
46 Balancing restrictions and access to maternity care for women and birthing partners during the COVID‐19 pandemic: the psychosocial impact of suboptimal care Joan Lalor, Susan Ayers, Joseph Agius et al. · BJOG An International Journal of Obstetrics & Gynaecology Open access 16 Jul 2021 67
47 Chorioamnionitis is essential in the evolution of bronchopulmonary dysplasia – The case in favour Wolfgang Thomas, Christian Paul Speer · Paediatric Respiratory Reviews 13 Oct 2013 65
48 Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy Peyman Hadji, M. Ziller, Dirk Guenter Kieback et al. · Annals of Oncology Open access 14 Feb 2009 63
49 Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40) Gϋnter von Minckwitz, Silvia Darb‐Esfahani, Sibylle Loibl et al. · Breast Cancer Research and Treatment 11 Jun 2011 61
50 Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer Matthias Christgen et al. · Cancer Open access 11 Aug 2020 57

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.